Cargando…

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein

BACKGROUND: With a US Food and Drug Administration-labeled indication to treat attention-deficit/hyperactivity disorder (ADHD), the nonstimulant guanfacine has become the preferred α(2)-agonist for ADHD treatment. However, significant interindividual variability has been observed in response to guan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillis, Nancy K, Zhu, Hao-Jie, Markowitz, John S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173033/ https://www.ncbi.nlm.nih.gov/pubmed/21931492 http://dx.doi.org/10.2147/NDT.S24153

Ejemplares similares

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets
por: Inoue, Yuji, et al.
Publicado: (2019)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Is Ciprofloxacin a Substrate of P-glycoprotein?
por: Park, Miki Susanto, et al.
Publicado: (2011)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Effect of Enteral Guanfacine on Dexmedetomidine Use in the ICU
por: Fetters, Megan B., et al.
Publicado: (2022)

A Retrospective Analysis of Guanfacine for the Pharmacological Management of Delirium
por: Jiang, Shixie, et al.
Publicado: (2023)

Stressing the potential of guanfacine as a treatment for cocaine use disorder
por: Lustberg, Daniel, et al.
Publicado: (2020)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale
por: Arnsten, Amy F.T., et al.
Publicado: (2012)

Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions
por: Fukuyama, Kouji, et al.
Publicado: (2021)

Guanfacine as an effective drug for the treatment of tic disorder. Case report
por: Del Sol Calderon, P., et al.
Publicado: (2021)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Evaluation of Guanfacine as a Potential Medication for Alcohol Use Disorder in Long-Term Drinking Rats: Behavioral and Electrophysiological Findings
por: Fredriksson, Ida, et al.
Publicado: (2015)

Effects of alpha 2-adrenoceptor agonists dexmedetomidine and guanfacine on morphine analgesia and tolerance in rats
por: Gursoy, Sinan, et al.
Publicado: (2011)

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)

Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior
por: Freeman, Z T, et al.
Publicado: (2015)

Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2019)

Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration
por: Wagener, Nele, et al.
Publicado: (2022)

Noradrenergic Modulation of Learned and Innate Behaviors in Dopamine Transporter Knockout Rats by Guanfacine
por: Volnova, Anna, et al.
Publicado: (2023)

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss, Michael, et al.
Publicado: (2016)

Successful use of guanfacine in a patient with chronic refractory cough: A case report
por: Kirschen, Gregory W., et al.
Publicado: (2017)

Successful Treatment of Tourette Syndrome With a Combination of Guanfacine and Aripiprazole: A Case Series
por: George, Tikku, et al.
Publicado: (2023)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation
por: Senarathna, S M D K Ganga, et al.
Publicado: (2016)

Transepithelial transport of P-glycoprotein substrate by the Malpighian tubules of the desert locust
por: Rossi, Marta, et al.
Publicado: (2019)

Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model
por: Lukkes, J. L., et al.
Publicado: (2020)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species
por: Arnsten, Amy F.T.
Publicado: (2020)

Guanfacine inhibits interictal epileptiform events and sodium currents in prefrontal cortex pyramidal neurons
por: Pasierski, Michał, et al.
Publicado: (2023)

Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy
por: Ota, Toyosaku, et al.
Publicado: (2021)

Characterizing the binding interactions between P-glycoprotein and eight known cardiovascular transport substrates
por: Jagodinsky, Justin C, et al.
Publicado: (2015)

Method development and validation of Guanfacine in rat plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study
por: Goparaju, Suryanarayana Murthy, et al.
Publicado: (2013)

Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein.
por: Bain, L J, et al.
Publicado: (1997)

Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine
por: Sansoè, Giovanni, et al.
Publicado: (2016)

Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors
por: Poongavanam, Vasanthanathan, et al.
Publicado: (2012)

Multiclass Classifier for P-Glycoprotein Substrates, Inhibitors, and Non-Active Compounds
por: Mora Lagares, Liadys, et al.
Publicado: (2019)

HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein
por: Cianfriglia, Maurizio, et al.
Publicado: (2007)

A Comparison of the Anorectic Effect and Safety of the Alpha(2)-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity
por: Dudek, Magdalena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m63r34u95br6m65p1gmsaimt4u